NFKB1 and acute myeloid leukemia: Moreover, as constitutive NF-κB activation has been shown to occur at higher levels in LSCs than in HSPCs (78), blocking NF-κB O-GlcNAcylation holds potential to selectively eliminate LSCs, to prevent AML progression and relapse.